Sidley represented Aprea Therapeutics, Inc. in its US$98 million initial public offering (IPO) of common stock. Aprea is a Boston-based biopharmaceutical company, with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. Aprea issued 6,516,667 shares of its common stock at a price to the public of $15.00 per share, including the full exercise of the underwriters option to purchase 850,000 shares of additional common stock. The shares began trading on the Nasdaq Global Select Market on October 3, 2019, under the ticker symbol “APRE.” J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as joint book-running managers for the offering.
The multi-office Sidley IPO team was led by Geoffrey Levin and Istvan Hajdu and included Sam Gandhi, Kostian Ciko, Chirag Naidu, Sagar Sritharan and Alex Csordas. Kevin Blatchford, Michael Hyatte and Michael Kohler provided additional capital markets support. Corey Perry provided executive compensation advice with help from Julia Sprangers. Sam Tiu and Grace St. Vincent provided IP support. Food, drug and medical device regulatory matters were handled by Torrey Cope, Donielle McCutcheon, Maurits Lugard, Anna Pavlou, Carlo Felizardo and Corbin Santo. Katie Klaben advised on Section 16 reporting obligations. Dan Altman and Ryan Kelly handled tax matters.
